The current BCG vaccine which is being used to prevent TB is not very effective, it’s not very efficient, and there’s a big
issue with drug resistance in TB at the moment. So what we’ve done is we made a new TB vaccine by including in the vaccine a new adjuvant that stimulates
the immune system and it flags up as a vaccine to the immune system so you get
a much better cellular and humoral immune response against the TB antigen. We can make a better vaccine but it needs to be thermally stable so we can
transport it to places where the vaccine is needed. My name is Asel Sartbaeva. I’m a lecturer in Chemistry at the University of Bath. A majority of the vaccines have to be
kept refrigerated between two and eight degrees. It’s incredibly
restrictive and very narrow temperature range obviously and in most of the
countries around the world where you want to transport them, if there is no
electricity or if there’s no fridge, it’s impossible but
if we don’t need refrigeration then we will be able to bring those vaccines to people who need them. This is a new method where we apply an inorganic material – silica – to proteins and we make sort of a network
out of this inorganic material and this network consists of very strong covalent
bonds so once we make this silicon network around the proteins it keeps them intact and it keeps them from unraveling and spoiling. In this study, we looked at TB, a potential TB vaccine, but in general we are also looking
at other vaccines. We’ve already looked at tetanus, but also we think this vaccine will be applicable on many other vaccines in the future.